A randomized comparison of a dual therapy stent - which combines low-dose sirolimus delivery from an abluminal biodegradable polymer matrix with a covalently bound anti-CD34 antibody layer - with a paclitaxel-eluting stent showed that the dual therapy stent effectively controls neointimal proliferation and was shown to be safe and effective. Results of the REMEDEE trial were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation...
More...
More...